Vivek Ramaswamy trades top execs and adds stealthy vant to $3B sale, while his new partner tosses Myovant $350M
Roivant chief Vivek Ramaswamy will pick up his $3 billion check from Sumitomo Dainippon in exchange for his stake in 5 of his startup vants — along with an option on 6 more as well as an operations team to oversee their work. And as they follow through on the deal, we’re learning the identity of the 5th biotech in the umbrella deal — which turns out to be a stealth company which Ramaswamy bought up to pursue a gene therapy for cystic fibrosis.
Premium subscription required
Unlock this article along with other benefits by subscribing to one of our paid plans.